Literature DB >> 16971435

Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines.

Xiao-Song He1, Tyson H Holmes, Caiqiu Zhang, Kutubuddin Mahmood, George W Kemble, David B Lewis, Cornelia L Dekker, Harry B Greenberg, Ann M Arvin.   

Abstract

The patterns of cellular immune responses induced by live attenuated influenza vaccine (LAIV) versus those of the trivalent inactivated influenza vaccine (TIV) have not been studied extensively, especially in children. The goals of this study were to evaluate the effects of TIV and LAIV immunization on cellular immunity to live influenza A virus in children and adults and to explore factors associated with variations in responses to influenza vaccines among individuals. A gamma interferon (IFN-gamma) flow cytometry assay was used to measure IFN-gamma-producing (IFN-gamma+) NK and T cells in peripheral blood mononuclear cell cultures stimulated with a live influenza A virus strain before and after LAIV or TIV immunization of children and adults. The mean percentages of influenza A virus-specific IFN-gamma+ CD4 and CD8 T cells increased significantly after LAIV, but not TIV, immunization in children aged 5 to 9 years. No increases in the mean levels of influenza A virus-reactive IFN-gamma+ T cells and NK cells were observed in adults given LAIV or TIV. TIV induced a significant increase in influenza A virus-reactive T cells in 6-month- to 4-year-old children; LAIV was not evaluated in this age group. The postvaccination changes (n-fold) in the percentages of influenza A virus-reactive IFN-gamma+ T and NK cells in adults were highly variable and correlated inversely with the prevaccination percentages, in particular with that of the CD56(dim) NK cell subset. In conclusion, our findings identify age, type of vaccine, and prevaccination levels of immune reactivity to influenza A virus as factors significantly associated with the magnitude of cellular immune responses to influenza vaccines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16971435      PMCID: PMC1642596          DOI: 10.1128/JVI.01460-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

Review 1.  Cross-presentation: underlying mechanisms and role in immune surveillance.

Authors:  Kenneth L Rock; Lianjun Shen
Journal:  Immunol Rev       Date:  2005-10       Impact factor: 12.988

2.  Live attenuated and inactivated influenza vaccine in school-age children.

Authors:  W C Gruber; L H Taber; W P Glezen; R D Clover; T D Abell; R W Demmler; R B Couch
Journal:  Am J Dis Child       Date:  1990-05

3.  Natural killer cell cytotoxicity in elderly humans after influenza immunization.

Authors:  J Kutza; P Gross; D Kaye; D M Murasko
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

4.  Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules.

Authors:  K L Rock; L Rothstein; S Gamble; C Fleischacker
Journal:  J Immunol       Date:  1993-01-15       Impact factor: 5.422

5.  Cellular mechanisms involved in protection and recovery from influenza virus infection in immunodeficient mice.

Authors:  A Bot; A Reichlin; H Isobe; S Bot; J Schulman; W M Yokoyama; C A Bona
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

6.  Cytotoxic T lymphocyte responses of infants after natural infection or immunization with live cold-recombinant or inactivated influenza A virus vaccine.

Authors:  I N Mbawuike; P A Piedra; T R Cate; R B Couch
Journal:  J Med Virol       Date:  1996-10       Impact factor: 2.327

7.  Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators Group.

Authors:  W C Gruber; R B Belshe; J C King; J J Treanor; P A Piedra; P F Wright; G W Reed; E Anderson; F Newman
Journal:  J Infect Dis       Date:  1996-06       Impact factor: 5.226

8.  Natural killer (NK) cell response after vaccination of volunteers with killed influenza vaccine.

Authors:  J M Schapiro; Y Segev; L Rannon; M Alkan; B Rager-Zisman
Journal:  J Med Virol       Date:  1990-03       Impact factor: 2.327

Review 9.  The molecular cell biology of interferon-gamma and its receptor.

Authors:  M A Farrar; R D Schreiber
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

10.  Cytotoxic T-cell immunity to influenza.

Authors:  A J McMichael; F M Gotch; G R Noble; P A Beare
Journal:  N Engl J Med       Date:  1983-07-07       Impact factor: 91.245

View more
  155 in total

1.  The magnitude of local immunity in the lungs of mice induced by live attenuated influenza vaccines is determined by local viral replication and induction of cytokines.

Authors:  Yuk-Fai Lau; Celia Santos; Fernando J Torres-Vélez; Kanta Subbarao
Journal:  J Virol       Date:  2010-10-20       Impact factor: 5.103

Review 2.  Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?

Authors:  Amy B Heimberger; John H Sampson
Journal:  Neuro Oncol       Date:  2010-12-10       Impact factor: 12.300

3.  Preexisting Immunity, More Than Aging, Influences Influenza Vaccine Responses.

Authors:  Adrian J Reber; Jin Hyang Kim; Renata Biber; H Keipp Talbot; Laura A Coleman; Tatiana Chirkova; F Liaini Gross; Evelene Steward-Clark; Weiping Cao; Stacie Jefferson; Vic Veguilla; Eric Gillis; Jennifer Meece; Yaohui Bai; Heather Tatum; Kathy Hancock; James Stevens; Sarah Spencer; Jufu Chen; Paul Gargiullo; Elise Braun; Marie R Griffin; Maria Sundaram; Edward A Belongia; David K Shay; Jacqueline M Katz; Suryaprakash Sambhara
Journal:  Open Forum Infect Dis       Date:  2015-04-15       Impact factor: 3.835

4.  H2N2 live attenuated influenza vaccine is safe and immunogenic for healthy adult volunteers.

Authors:  Irina Isakova-Sivak; Marina Stukova; Mariana Erofeeva; Anatoly Naykhin; Svetlana Donina; Galina Petukhova; Victoria Kuznetsova; Irina Kiseleva; Tatiana Smolonogina; Irina Dubrovina; Maria Pisareva; Alexandra Nikiforova; Maureen Power; Jorge Flores; Larisa Rudenko
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Discordance between antibody and T cell responses in recipients of trivalent inactivated influenza vaccine.

Authors:  Mary Dawn T Co; Laura Orphin; John Cruz; Pamela Pazoles; Alan L Rothman; Francis A Ennis; Masanori Terajima
Journal:  Vaccine       Date:  2008-02-26       Impact factor: 3.641

6.  Association of Prior Vaccination With Influenza Vaccine Effectiveness in Children Receiving Live Attenuated or Inactivated Vaccine.

Authors:  Huong Q McLean; Herve Caspard; Marie R Griffin; Manjusha Gaglani; Timothy R Peters; Katherine A Poehling; Christopher S Ambrose; Edward A Belongia
Journal:  JAMA Netw Open       Date:  2018-10-05

7.  Seasonal Influenza Vaccination of Children Induces Humoral and Cell-Mediated Immunity Beyond the Current Season: Cross-reactivity With Past and Future Strains.

Authors:  Adrian J Reber; Jin Hyang Kim; Laura A Coleman; Sarah M Spencer; Jessie R Chung; Jufu Chen; Paul Gargiullo; Maria E Sundaram; Edward A Belongia; David K Shay; Jacqueline M Katz; Suryaprakash Sambhara
Journal:  J Infect Dis       Date:  2016-08-28       Impact factor: 5.226

Review 8.  Influenza vaccines: challenges and solutions.

Authors:  Katherine Houser; Kanta Subbarao
Journal:  Cell Host Microbe       Date:  2015-03-11       Impact factor: 21.023

Review 9.  Broadly neutralizing antibodies against influenza viruses.

Authors:  Nick S Laursen; Ian A Wilson
Journal:  Antiviral Res       Date:  2013-04-09       Impact factor: 5.970

Review 10.  Influenza vaccination for patients with chronic obstructive pulmonary disease: understanding immunogenicity, efficacy and effectiveness.

Authors:  Farzaneh Sanei; Tom Wilkinson
Journal:  Ther Adv Respir Dis       Date:  2016-05-18       Impact factor: 4.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.